United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Veracity Capital LLC

Veracity Capital LLC trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 43.6% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 1,422 shares of the biotechnology company's stock after selling 1,101 shares during the quarter. Veracity Capital LLC's holdings in United Therapeutics were worth $438,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Signaturefd LLC boosted its holdings in shares of United Therapeutics by 4.7% during the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock valued at $234,000 after acquiring an additional 30 shares during the last quarter. Parallel Advisors LLC lifted its position in United Therapeutics by 2.8% during the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock valued at $385,000 after purchasing an additional 30 shares during the period. Anchor Investment Management LLC grew its position in United Therapeutics by 12.0% in the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 30 shares during the period. Great Lakes Advisors LLC lifted its holdings in shares of United Therapeutics by 1.6% during the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock valued at $697,000 after buying an additional 31 shares during the period. Finally, Oregon Public Employees Retirement Fund increased its position in United Therapeutics by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock valued at $3,214,000 after acquiring an additional 33 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

UTHR has been the subject of a number of recent research reports. Wells Fargo & Company restated an "equal weight" rating and set a $314.00 price target (down from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. HC Wainwright restated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research report on Monday, May 5th. Cantor Fitzgerald began coverage on shares of United Therapeutics in a report on Monday. They set an "overweight" rating and a $405.00 target price for the company. Morgan Stanley raised their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research note on Thursday, May 1st. Finally, Bank of America upgraded shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price for the company in a report on Monday, April 21st. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $393.00.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded down $4.26 during trading hours on Thursday, hitting $319.71. The company's stock had a trading volume of 416,682 shares, compared to its average volume of 439,941. The firm's fifty day moving average price is $300.45 and its 200 day moving average price is $334.10. United Therapeutics Co. has a 52 week low of $266.98 and a 52 week high of $417.82. The company has a market capitalization of $14.42 billion, a price-to-earnings ratio of 14.04, a P/E/G ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business's quarterly revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the firm posted $6.17 earnings per share. On average, equities research analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $316.07, for a total value of $3,476,770.00. Following the sale, the executive vice president now owns 36,781 shares in the company, valued at $11,625,370.67. This represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Raymond Dwek sold 3,000 shares of the stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $285.57, for a total transaction of $856,710.00. Following the sale, the director now directly owns 1,750 shares in the company, valued at approximately $499,747.50. The trade was a 63.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 56,500 shares of company stock valued at $16,923,950. 10.30% of the stock is owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.